Asia · Regional markets · CNBC-TV18

Aarti Drugs' Baddi facility in Himachal Pradesh gets 3 US FDA Form 483 observations

Published by CNBC-TV18 · India 8 h ago

Aarti Drugs said its subsidiary Pinnacle Life Science received three Form 483 observations from the US FDA after an inspection of its Baddi formulations facility between November…

Read the full article on CNBC-TV18 Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.cnbctv18.com)

Also worth reading

Tech in Asia

OpenAI raises $11b at $1.25t valuation in funding round

The Business Times

From AI financing to Indonesia outlook: 4 takeaways from Singapore banks’ Q3 results

Mint

Aarti Drugs' Baddi facility in Himachal Pradesh gets 3 US FDA Form 483 observations

Share

Also worth reading

OpenAI raises $11b at $1.25t valuation in funding round

From AI financing to Indonesia outlook: 4 takeaways from Singapore banks’ Q3 results

Arini’s Hedge Fund Losses Grow to 32% as It Sells Some Positions

Nasdaq rebounds but posts fourth straight weekly decline

Samvat 2082: Commodities witness sharp volatility as crude surges

IOC, BPCL, HPCL reject Karnataka’s claim of excess ethanol in petrol